Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Altasciences and Virpax Pharmaceuticals Enter Clinical Trial Partnership | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Altasciences and Virpax Pharmaceuticals Enter Clinical Trial Partnership

Altasciences to conduct first-in-human study of Epoladerm for chronic pain associated with osteoarthritis of the knee.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Altasciences has been chosen by Virpax Pharmaceuticals to conduct a first-in-human study of Epoladerm (diclofenac epolamine) for chronic pain associated with osteoarthritis of the knee. This treatment is supplied in a pre-filled device for administration as a topical spray film.

The study will be conducted in Q2 2022 at Altasciences’ clinical pharmacology unit in Montreal, Canada.

“We look forward to working with Altasciences to accelerate the development of this analgesic treatment and provide robust data in support of the 505(b)(2) FDA approval pathway,” said Virpax’s chairman and CEO, Anthony P. Mack.

Virpax’s proprietary technology provides a pre-filled canister for the therapeutic application of a clear, fast-drying spray film that is thinner than a standard liquid bandage. This technology offers convenience and eliminates the need for messy creams or gels.

Altasciences leverages decades of experience conducting first-in-human clinical trials, a vast database of study participants, and state-of-the-art bioanalytical facilities to provide expert guidance and personalized solutions.

Ingrid Holmes, Altasciences’ vice president, global clinical operations, said, “We are proud to partner with Virpax to help move this important therapeutic further along the path to regulatory approval.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics